|
A leading researcher in angiogenesis and vascular cell biology, Dr. Shima worked during the early 1990’s on pioneering studies that elucidated the role of Vascular Endothelial Growth Factor (VEGF) during pathological neovascularization within the eye.
Dr. Shima received his Ph.D. in 1995 from the Program in Cell and Developmental Biology, Harvard University. In 1999, Dr. Shima was appointed the head of the Endothelial Cell Biology Laboratory at the Imperial Cancer Research Fund in London, England. In 2002, Dr. Shima joined Eyetech Pharmaceuticals, where he established and led a multidisciplinary R&D facility, delivered product candidates in ocular neovascular disease and ocular drug delivery and was part of the senior management team responsible for the approval and commercialization of the first anti-VEGF drug for AMD. Dr. Shima is currently the Rothes Professor of Translational Vision Research at UCL’s Institute of Ophthalmology. | 